Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119249 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
A Phase 2 study of Stage IV Melanoma and Stage III Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT00119249: Completed Phase 2 study of Stage IV Melanoma and Stage III Melanoma, sponsored by National Cancer Institute (NCI).
NCT00119249 is a Phase 2 study of Stage IV Melanoma and Stage III Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants, above the 41-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (80% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00119249, a Phase 2 study of Stage IV Melanoma and Stage III Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery
Primary Outcome
The overall response rate along with subgroup-specific response rates will be estimated at the end of the trial along with 95% confidence interval.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG sorafenib tosylate
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00119249 record still lists
NCT00119249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 41-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (80% higher).
The record links to 2 conditions, with Stage IV Melanoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00119249 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00119249 about?
NCT00119249 is a clinical study titled "Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery". Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery
What is the current status of trial NCT00119249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2005-06.
What conditions does trial NCT00119249 study?
This clinical trial studies the following conditions: Stage IV Melanoma, Stage III Melanoma.
What interventions are being tested in trial NCT00119249?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00119249?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00119249 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00119249's enrollment target sits among peer trials
74 3rd of 13 higher than 11 of 13 other Stage IV Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
COMPLETED · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
-
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia